Is MNKD Worth Buying in 2026?

Mannkind Corporation

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-08-16

Here’s whether Mannkind Corporation (MNKD) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: 50-day MA is rising (+2.23% over 10 days); RSI 47 — healthy momentum range; 3-month momentum positive (+24.6%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative). Currently 40.9% off its 52-week high. Score: +0/7.

Ready to act on this? 📈 Trade on Webull

MNKD is trading below its 200-day MA ($4.26) — a key warning sign the longer-term trend is under pressure. An RSI of 47.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +4.0% compares to +20.4% for SPY (trailed the market by 16.3%). The current 40.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $10,405 today
vs. S&P 500 (SPY) — same period trailed market by 16.3%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($4.26)
Above 50-day MA ($3.94)
RSI(14) neutral zone (30–70) — currently 47.4
Positive return (+4.0%)
!Within 10% of period high (−40.9%)
Period Range $3.85
$2.23 $6.51
RSI (14) 47.4
0 · OversoldOverbought · 100

Key Metrics

Price$3.85
Period Return+4.0%
Period High$6.51
Period Low$2.23
Drawdown−40.9%
MA-50$3.94
MA-200$4.26
RSI (14)47.4
Avg Volume (30d)4.7M
vs. SPYtrailed by 16.3%
Return Rank#640 of 1252

Trade MNKD

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers